Knight Therapeutics Secures Rights To Rigel’s Fostamatinib In Latin America
Knight Therapeutics Inc. (TSX: GUD) (OTC: KHTRF)
Profounda Reports FDA Granted Co. Orphan Drug Designation Approval For Treatment Of Invasive Candidiasis With Miltefosine; BZ NOTE: Co. Licensed Miltefosine From Knight Therapeutics In 2013
- Invasive candidiasis is an infection caused by a yeast (a type of fungus) called Candida. and is a serious infection that can affect the blood, heart, brain, eyes, bones, or other parts of the body.
- In the United
Knight Therapeutics Announces Health Canada Approval For NERLYNX To Treat HER2-Positive Metastatic Breast Cancer
Knight Therapeutics Inc. (TSX:GUD), ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that Health Canada has approved NERLYNX® (neratinib) in combination with capecitabine